FDA批准摘要:奥拉帕利联合阿比特龙治疗BRCA突变转移性去势抵抗性前列腺癌患者
本文总结美国食品药品监督管理局(FDA)审评支持批准奥拉帕利联合阿比特龙用于经FDA批准的伴随诊断检测确定存在有害或疑似有害BRCA突变(BRCAm)的转移性去势抵抗性前列腺癌(mCRPC)患者的数据。批准基于PROpel双盲试验,796例mCRPC患者随机接受阿比特龙联合泼尼松或泼尼松龙加奥拉帕利或安慰剂。意向治疗人群rPFS中位25个月 vs 17个月,HR 0.66(95%CI 0.54-0.81);BRCAm亚组85例rPFS HR 0.24(95%CI 0.12-0.45),OS HR 0.30(95%CI 0.15-0.59)。
要点
- FDA基于PROpel试验批准奥拉帕利联合阿比特龙用于BRCAm mCRPC患者。
- 意向治疗人群rPFS中位25个月 vs 17个月,HR 0.66(95%CI 0.54-0.81)。
- BRCAm亚组85例rPFS HR 0.24(95%CI 0.12-0.45),OS HR 0.30(95%CI 0.15-0.59)。
核心结论
- 在mCRPC患者中,奥拉帕利联合阿比特龙的疗效主要归因于BRCAm亚组的治疗效应,该亚组为批准的适应人群。
- 对于无BRCAm的患者,FDA判定rPFS的适度改善合并临床显著毒性未能显示有利的风险/获益评估。
研究设计与样本
- FDA审评总结,基于PROpel双盲试验,随机分配796例mCRPC患者接受阿比特龙联合泼尼松或泼尼松龙加奥拉帕利或安慰剂。
- 主要终点为研究者评估的影像学无进展生存期(rPFS)。
主要发现
- 意向治疗人群rPFS中位25个月 vs 17个月,HR 0.66(95%CI 0.54-0.81),差异有统计学显著性。
- BRCAm mCRPC亚组85例探索性分析:rPFS HR 0.24(95%CI 0.12-0.45),OS HR 0.30(95%CI 0.15-0.59)。
- 无明确BRCA突变亚组711例探索性分析:rPFS HR 0.77(95%CI 0.63-0.96),OS HR 0.92(95%CI 0.74-1.14)。
- 加用奥拉帕利导致毒性增加,包括需要输血的贫血发生于18%的患者。
关键数值与推荐
- 批准适应人群为经FDA批准的伴随诊断检测确定存在有害或疑似有害BRCA突变的mCRPC患者。
- BRCAm亚组85例rPFS HR 0.24(95%CI 0.12-0.45),OS HR 0.30(95%CI 0.15-0.59)。
- 无BRCA突变亚组711例rPFS HR 0.77(95%CI 0.63-0.96),OS HR 0.92(95%CI 0.74-1.14)。
临床怎么用
- FDA批准奥拉帕利联合阿比特龙用于经伴随诊断检测确定BRCA突变的mCRPC患者。
- 对于无BRCAm的患者,FDA判定rPFS的适度改善合并临床显著毒性未能显示有利的风险/获益评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This article summarizes the US Food and Drug Administration (FDA) review of the data leading to approval of olaparib plus abiraterone for the treatment of patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test. PATIENTS AND METHODS: Approval was based on the results from PROpel, a double-blind trial that randomly assigned 796 patients with mCRPC to abiraterone plus prednisone or prednisolone with either olaparib or placebo. The primary end point was radiographic progression-free survival (rPFS) per investigator assessment. RESULTS: There was a statistically significant improvement in rPFS for olaparib plus abiraterone versus placebo plus abiraterone, with a median rPFS of 25 versus 17 months and a hazard ratio (HR) of 0.66 (95% CI, 0.54 to 0.81) in the intention-to-treat population. In an exploratory analysis of the subgroup of 85 patients with BRCAm mCRPC, the HR for rPFS was 0.24 (95% CI, 0.12 to 0.45) and the HR for overall survival (OS) was 0.30 (95% CI, 0.15 to 0.59). In an exploratory analysis of the subgroup of 711 patients without an identified BRCA mutation, the HR for rPFS was 0.77 (95% CI, 0.63 to 0.96) and the HR for OS was 0.92 (95% CI, 0.74 to 1.14). Adding olaparib to abiraterone resulted in increased toxicity, including anemia requiring transfusion in 18% of patients. CONCLUSION: In patients with mCRPC, efficacy of the combination of olaparib plus abiraterone was primarily attributed to the treatment effect in the BRCAm subgroup, the indicated population for the approval. For patients without BRCAm, the FDA determined that the modest rPFS improvement, combined with clinically significant toxicities, did not demonstrate a favorable risk/benefit assessment.
引用
- Fallah J, Xu J, Weinstock C, et al. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023. PMID: 38127780. doi:10.1200/JCO.23.01868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。